Heparin-induced thrombocytopenia in the ICU: An overview

Critical Care

Volumn 15, Issue 2, 2011, Pages

  Sakr, Yasser ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; ARGATROBAN; CYCLIC AMP; DANAPAROID; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; GLYCOSAMINOGLYCAN; HEPARIN; HEPARINOID; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4; VANCOMYCIN; ANTICOAGULANT AGENT; ANTITHROMBIN; POLYSACCHARIDE;

ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DIALYSIS; DRUG BINDING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTENSIVE CARE UNIT; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SEPSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANTICOAGULANTS; ANTITHROMBINS; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; HEPARIN; HEPARINOIDS; HUMANS; IMMUNOLOGIC TESTS; PLATELET ACTIVATION; PLATELET FACTOR 4; POLYSACCHARIDES; THROMBOCYTOPENIA;

EID: 79953011172     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9993     Document Type: Review

References (54)

1. Thong CL, Kam PCA. Heparin-induced thrombocytopenia. Curr Anaesth Crit Care 2005, 16:143-150.
2. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005, 106:2921-2922. 10.1182/blood-2005-05-1824, 16204152.
3. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007, 35:1165-1176. 10.1097/01.CCM.0000259538.02375.A5, 17334253.
4. Picker SM, Gathof BS. Heparin induced thrombocytopenia. A frequently unrecognised complication after major orthopedic surgery. Orthopade 2004, 33:1300-1308. 10.1007/s00132-004-0695-3, 15278277.
5. Battistelli S, Genovese A, Gori T. Heparin-induced thrombocytopenia in surgical patients. Am J Surg 2010, 199:43-51. 10.1016/j.amjsurg.2009.01.029, 20103065.
6. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006, 118:165-176. 10.1016/j.thromres.2005.07.012, 16139874.
7. Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996, 52:90-95. 10.1002/(SICI)1096-8652(199606)52:2<90::AID-AJH4>3.0.CO;2-0, 8638647.
8. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995, 332:1374-1376. 10.1056/NEJM199505183322011, 7715648.
9. Shoenfeld Y, Praprotnik S, Levy Y, et al. Pathogenic anti-endothelial cell antibodies: classification to anti-microvascular EC and anti-macrovascular EC antibodies. Isr Med Assoc J 2000, (2 Suppl):24-25.
10. Khairy M, Lasne D, Amelot A, et al. Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood. Thromb Haemost 2004, 92:1411-1419.
11. Davidson SJ, Wadham P, Rogers L, Burman JF. Endothelial cell damage in heparin-Induced thrombocytopenia. Blood Coagul Fibrinolysis 2007, 18:317-320. 10.1097/MBC.0b013e32806a8249, 17473571.
12. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005, 106:3791-3796. 10.1182/blood-2005-05-1938, 1895104, 16109780.
13. Arepally GM, Hursting MJ. Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. J Thromb Thrombolysis 2008, 26:55-61. 10.1007/s11239-008-0217-y, 18369708.
14. Hassan Y, Awaisu A, Aziz NA, Aziz NH, Ismail O. Heparin-induced thrombocytopenia and recent advances in its therapy. J Clin Pharm Ther 2007, 32:535-544. 10.1111/j.1365-2710.2007.00865.x, 18021330.
15. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002, 122:37-42. 10.1378/chest.122.1.37, 12114336.
16. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:340S-380S. 10.1378/chest.08-0677, 18574270.
17. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005, 146:341-346. 10.1016/j.lab.2005.08.003, 16310517.
18. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007, 21:589-607. 10.1016/j.hoc.2007.06.004, 17666280.
19. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009, 135:1651-1664. 10.1378/chest.08-2830, 19497901.
20. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998, 79:1-7.
21. Warkentin TE, Crowther MA. When is HIT really HIT?. Ann Thorac Surg 2007, 83:21-23. 10.1016/j.athoracsur.2006.07.006, 17184624.
22. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000, 96:846-851.
23. Cawley MJ, Wittbrodt ET, Boyce EG, Skaar DJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy 1999, 19:108-113. 10.1592/phco.19.1.108.30518, 9917084.
24. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28:1871-1876. 10.1097/00003246-200006000-00031, 10890635.
25. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003, 24:607-622. 10.1016/S0272-5231(03)00100-X, 14710693.
26. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical fea tures of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005, 94:132-135.
27. Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008, 29:66-74. 10.1055/s-2008-1047564, 18302088.
28. Pohl C, Klockgether T, Greinacher A, Hanfl and P, Harbrecht U. Neurological complications in heparin-induced thrombocytopenia. Lancet 1999, 353:1678-1679. 10.1016/S0140-6736(99)01089-2, 10335796.
29. Wester JP, Haas FJ, Biesma DH, Leusink JA, Veth G. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients. Intensive Care Med 2004, 30:1927-1934. 10.1007/s00134-004-2334-1, 15156309.
30. Warkentin TE. Heparin-induced thrombocytopenia. Dis Mon 2005, 51:141-149. 10.1016/j.disamonth.2005.03.009, 15900266.
31. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003, 2:148-157.
32. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4:759-765. 10.1111/j.1538-7836.2006.01787.x, 16634744.
33. Schallmoser K, Drexler C, Rohde E, et al. The particle gel immunoassay as a rapid test to rule out heparin-induced thrombocytopenia?. J Thorac Cardiovasc Surg 2009, 137:781-783. 10.1016/j.jtcvs.2008.03.044, 19258119.
34. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006, 2386-2393. 10.1161/01.ATV.0000238350.89477.88, 16873726.
35. Shaheed G, Malkovska V, Mendoza J, et al. PF4 ENHANCED assay for the diagnosis of heparin-induced thrombocytopenia in complex medical and surgical patients. Crit Care Med 2007, 35:1691-1695. 10.1097/01.CCM.0000268057.62578.3A, 17507826.
36. Parker RI. Measurement of heparin-dependent platelet antibodies in the diagnosis of heparin-induced thrombocytopenia: fact or fiction?. Crit Care Med 2007, 35:1784-1785. 10.1097/01.CCM.0000269359.71847.66, 17581366.
37. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121:535-555. 10.1046/j.1365-2141.2003.04334.x, 12752095.
38. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999, 82:439-447.
39. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:311S-337S. 10.1378/chest.126.3_suppl.311S, 15383477.
40. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005, 3:2428-2436. 10.1111/j.1538-7836.2005.01623.x, 16241940.
41. Tardy-Poncet B, Wolf M, Lasne D, et al. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases. Intensive Care Med 2009, 35:1449-1453. 10.1007/s00134-009-1464-x, 19350215.
42. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003, 110:73-82. 10.1016/S0049-3848(03)00336-0, 12893020.
43. Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther 2004, 2:339-357. 10.1586/14779072.2.3.339, 15151481.
44. Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999, 115:1616-1620. 10.1378/chest.115.6.1616, 10378558.
45. Keegan SP, Gallagher EM, Ernst NE, Young EJ, Mueller EW. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother 2009, 43:19-27. 10.1345/aph.1L224, 19116377.
46. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
47. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008, 99:830-839.
48. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007, 83:572-577. 10.1016/j.athoracsur.2006.09.038, 17257990.
49. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008, 99:208-214.
50. Warkentin TE. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)-bridging the River Coumarin. Thromb Haemost 2008, 99:2-3.
51. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. J Thromb Haemost 2006, 4:894-896. 10.1111/j.1538-7836.2006.01875.x, 16634761.
52. Hilbert P, Teumer P, Stuttmann R. Prevention of thromboembolism in German intensive care units: Results of a nationwide survey. Anaesthesist 2008, 57:242-250. 10.1007/s00101-008-1309-y, 18256805.
53. Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005, 20:348-353. 10.1016/j.jcrc.2005.09.008, 16310606.
54. Baldwin ZK, Spitzer AL, Ng VL, Harken AH. Contemporary standards for the diagnosis and treatment of heparin-induced thrombocytopenia (HIT). Surgery 2008, 143:305-312. 10.1016/j.surg.2007.09.036, 18291250.